Trials / Completed
CompletedNCT00830180
Open Label Extension In Cancer Patients
PHASE 2 OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of anti-NGF AB in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Anti-NGF AB | Solution for injection, 10 mg, one injection/8 weeks |
Timeline
- Start date
- 2009-10-29
- Primary completion
- 2013-02-14
- Completion
- 2013-02-14
- First posted
- 2009-01-27
- Last updated
- 2021-04-05
- Results posted
- 2021-02-02
Locations
23 sites across 10 countries: United States, Austria, Bosnia and Herzegovina, Croatia, Hungary, India, Latvia, Poland, Slovakia, South Korea
Source: ClinicalTrials.gov record NCT00830180. Inclusion in this directory is not an endorsement.